HEXADRONE
11.12.2023 08:31:35 CET | Business Wire | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH.
The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more.
“Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European airspace legally, in accordance with categories C5 and C6, from 2024.
The exceptional modularity of the TUNDRA 2 offers reliable technical solutions for a variety of sectors. Due to its standardized interfaces, it can be easily extended using a multitude of addons while maintaining its compliance with current standards,”- says Alexandre Labesse, CEO of Hexadrone.
NavCert GmbH (NB 2603), currently chairs the coordination group of notified bodies for unmanned aircraft systems in accordance with the Delegated Regulation(EU) 2019/945. NavCert GmbH is one of the three entities in Europe which are appointed to perform C5/C6 class drone conformity tests, to be operated within the category specific, for performing operations Beyond Ground Observation (BGO) also known as Beyond Vision Line Of Sight (BVLOS).
Marcel Visser, CEO of NavCert GmbH, stated, “Congratulations to Hexadrone on being first confirming both multicopter C5 and C6 Drone specification compliancy to Delegated Regulation (EU) 2019/945. We are honored to be the Notified Body (NB 2603) selected by Hexadrone to perform Type Examinations for both version of the Tundra 2. Our extensive experience and our contribution to the development of the EN 4709 standard have been invaluable in conducting the technical assessments on unmanned aircraft systems for civil use. We remain dedicated to upholding the requisite standards of quality and safety for drone operations within the European Union."
*****
Starting 2024, Hexadrone is accelerating it’s worldwide expansion by selecting and recruiting Specialised resellers over the Globe.
About Hexadrone
Through its three Departments, Hexadrone is recognized as an expert in designing and manufacturing a modular UAV that gives customers a valuable investment for their activity. Founded in 2014, Hexadrone was initially providing a web platform to resel UAV components and quickly moved to the UAV custom assembling. Based on the user’s experiences feedback, Hexadrone has understood that a universal and modular platform was the answer to the market and after the first Version of the TUNDRA Hexadrone has built a factory to design and to manufacture a multi-purpose drone for professionals.
Today, the production capacity allowed to manufacture up to 1000 TUNDRA 2 units per year.
About NavCert GmbH
NavCert is the first laboratory ever accredited in Europe in the field of GNSS, nowadays with a flexible scope, a remarkable USP achievement. The firm provides worldwide technical services, like expert opinion, verification, validation, and voluntary certification services in the areas of precise positioning/localization, navigation, velocity and timing. Furthermore, NavCert is accredited as certification body for unmanned aircraft systems (UAS) by the Deutsche Akkreditierungsstelle (DAkkS) and is notified (NB 2603) by the German Federal Office of Civil Aeronautics for the EU Type Examination of fixed-wing, copter and multicopter UAS in classes C0 to C4 in the Open Category and C5 to C6 in the Specific Category according to the Delegated Regulation (EU) 2019/945 incl. referred standards. NavCert chairs the coordination group of notified bodies for UAS. These activities are complemented by GAP analysis of specification and documentation and pre-testing. For additional information, please visit NavCert website at www.navcert.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231210550915/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom